Please use this identifier to cite or link to this item:
Scopus Web of ScienceĀ® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChapman, I.en
dc.contributor.authorParker, B.en
dc.contributor.authorDoran, S.en
dc.contributor.authorFeinle-Bisset, C.en
dc.contributor.authorWishart, J.en
dc.contributor.authorLush, C.en
dc.contributor.authorChen, K.en
dc.contributor.authorLaCerte, C.en
dc.contributor.authorBurns, C.en
dc.contributor.authorMcKay, R.en
dc.contributor.authorWeyer, C.en
dc.contributor.authorHorowitz, M.en
dc.identifier.citationObesity, 2007; 15(5):1179-1186en
dc.description.abstractOBJECTIVE: We previously reported that a single preprandial injection (120 microg) of pramlintide, an analog of the beta-cell hormone amylin, reduced ad libitum food intake in obese subjects. To further characterize the meal-related effects of amylin signaling in humans, we studied a lower pramlintide dose (30 microg) in normal-weight subjects. RESEARCH METHODS AND PROCEDURES: In a randomized, double-blind, placebo-controlled, cross-over study, 15 healthy men (age, 24 +/- 7 years; BMI, 22.2 +/- 1.8 kg/m(2)) underwent a standardized buffet meal test on two occasions. After an overnight fast, subjects received a single subcutaneous injection of pramlintide (30 microg) or placebo, followed immediately by a standardized pre-load meal. After 1 hour, subjects were offered an ad libitum buffet meal, and total caloric intake and meal duration were measured. RESULTS: Compared with placebo, pramlintide reduced total caloric intake (1411 +/- 94 vs. 1190 +/- 117 kcal; Delta, -221 +/- 101 kcal; -14 +/- 9%; p = 0.05) and meal duration (36 +/- 2 vs. 31 +/- 3 minutes; Delta, -5.1 +/- 1.4 minutes; p < 0.005). Visual analog scale profiles of hunger trended lower and fullness higher during the first hour after pramlintide administration. In response to the buffet, hunger and fullness changed to a similar degree after pramlintide and placebo, despite subjects on pramlintide consuming 14% fewer kilocalories. Visual analog scale nausea ratings remained near baseline, without differences between treatments. Plasma peptide YY, cholecystokinin, and ghrelin concentrations did not differ with treatment, whereas glucagon-like peptide-1 concentrations after meals were lower in response to pramlintide than to placebo. DISCUSSION: These observations add support to the concept that amylin agonism may have a role in human appetite control.en
dc.description.statementofresponsibilityIan Chapman, Barbara Parker, Selena Doran, Christine Feinle-Bisset, Judith Wishart, Cameron W. Lush, Kim Chen, Carl LaCerte, Colleen Burns, Robyn McKay, Christian Weyer and Michael Horowitzen
dc.publisherNorth Amer Assoc Study Obesityen
dc.subjectpeptide hormones; buffet meal; satiation; hunger; satietyen
dc.titleLow-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjectsen
dc.typeJournal articleen
pubs.library.collectionMedicine publicationsen
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.